International news network BBN Breaking has reported news of LTR Pharma’s completion of manufacturing validation for SPONTAN this week.
Describing SPONTAN as a “game-changer in Erectile Dysfunction treatment”, the article highlights the significance of meeting all the prerequisites for a pivotal FDA clinical study as the Company prepares to commence patient recruitment for the bioequivalence study.